RADIATION THERAPY ONCOLOGY GROUP

放射治疗肿瘤学组

• 批准号: 3556120
• 负责人: CARLOS A. PEREZ
• 金额: $ 24.33万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-02-01 至 1989-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3556120
• 关键词: Hodgkin's disease; bladder neoplasm; breast neoplasms; cervix neoplasms; combination cancer therapy; cooperative study; cyclophosphamide; doxorubicin; head /neck neoplasm; human subject; human therapy evaluation; hyperbaric oxygen therapy; levamisole; lung neoplasms; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer palliative treatment; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer thermotherapy; patient /disease registry; pediatric neoplasm /cancer; prednisone; radiation therapy dosage; radiobiology; radiosensitizer; rectum neoplasms; rhabdomyosarcoma; vincristine

The Division of Radiation Oncology at Washington University proposes to: 1) Continue participation in clinical trials of the Radiation Therapy Oncology Group; 2) contribute to the scientific contents of group studies and to actively engage in protocol design and coordination; 3) assist in administrative and organizational matters of the group outlined by the Chairman of the Group and Committee Chairmen; 4) participate in the analysis of scientific data generated by the Radiation Therapy Oncology Group and to prepare manuscripts to be submitted for publication to reputable scientific journals; 5) promote clinical trials within the framework of cooperative groups at Washington University School of Medicine. The Division has consistently been one of the major contributors of patients to RTOG protocol studies. Approximately 50% of the patients accessioned to the studies have been in non-metastatic protocols. The projected number of patients to be entered in protocol studies during the year 1979 will be in the range of 90 to 100. The Division participates in the avant-garde protocols in radiation oncology that require specialized facilities and equipment such as the hyperthermia and hypoxic sensitizers.

华盛顿大学放射肿瘤学部建议：1) 继续参与放射治疗肿瘤学的临床试验 团体; 2) 为小组研究的科学内容做出贡献并积极 参与协议设计和协调； 3）协助行政及 集团主席概述的集团组织事项以及 委员会主席； 4）参与分析产生的科学数据 由放射治疗肿瘤学组负责并准备手稿 提交至知名科学期刊发表； 5）促进临床 华盛顿大学合作小组框架内的试验 医学院。 该部门一直是主要部门之一 RTOG 方案研究的患者贡献者。 大约 50% 参与研究的患者均处于非转移性方案中。 这 预计年内将参与方案研究的患者人数 1979年将在90至100之间。该司参加 需要专门设施的放射肿瘤学先锋方案 以及热疗和缺氧敏化剂等设备。